Modeling synovial sarcoma metastasis in the mouse:
PI3′-lipid signaling and inflammation


1Department of Orthopaedics, 2Department of Oncological Sciences, 3Huntsman Cancer Institute, 4Department of Bioinformatics, 5Department of Pathology, and 6Department of Human Genetics, University of Utah, Salt Lake City, UT 84112
7Departments of Pathology and Translational Molecular Pathology and 8Sarcoma Medical Oncology, M.D. Anderson Cancer Center, Houston, TX 77030

Solid tumor metastasis is a complex biology, impinged upon by a variety of dysregulated signaling pathways. PI3′-lipid signaling has been associated with metastasis and inflammation in many cancers, but the relationship between tumor cell–intrinsic PI3′-lipid signaling and inflammatory cell recruitment has remained enigmatic. Elevated PI3′-lipid signaling associates with progression of synovial sarcoma, a deadly soft tissue malignancy initiated by a t(X;18) chromosomal translocation that generates an SS18-SSX fusion oncprotein. Here, we show in genetically engineered mouse models of locally induced expression of SS18-SSX1 or SS18-SSX2 that Pten silencing dramatically accelerated and enhanced sarcomagenesis without compromising synovial sarcoma characteristics. PTEN deficiency increased tumor angiogenesis, promoted inflammatory gene expression, and enabled highly penetrant spontaneous pulmonary metastasis. PTEN-deficient sarcomas revealed infiltrating myeloid-derived hematopoietic cells, particularly macrophages and neutrophils, recruited via PI3′-lipid–induced CSF1 expression in tumor cells. Moreover, in a large panel of human synovial sarcomas, enhanced PI3′-lipid signaling also correlated with increased inflammatory cell recruitment and CSF1R signal transduction in both macrophages and endothelial cells. Thus, both in the mouse model and in human synovial sarcomas, PI3′-lipid signaling drives CSF1 expression and associates with increased infiltration of the monocyte/macrophage lineage as well as neutrophils.

INTRODUCTION

Synovial sarcoma (SS) is the most common soft-tissue sarcoma in adolescents and young adults (Herzog, 2005). Once metastatic, it is usually incurable. Characterized by a balanced t(X;18) chromosomal translocation that produces an SS18-SSX fusion oncogene (Ture–Carel et al., 1987; Clark et al., 1994; de Leeuw et al., 1995), SS has been shown to require few other genetic derangements beyond the fusion (Barretina et al., 2010; Przybyl et al., 2014; Mikami et al., 2015; Vlenterie et al., 2015; Jones et al., 2016).

Expression of either SS18-SSX1 or SS18-SSX2 has proven sufficient to drive synovial sarcomagenesis in the mouse (Haldar et al., 2007, 2009; Jones et al., 2016). These models, and most genetic models of fusion oncogene–driven sarcomagenesis, have fallen slightly short of displaying the full biology of metastasis (Haldar et al., 2007, 2009; Straessler et al., 2013; Goodwin et al., 2014; Jones et al., 2016). This has raised the question of what additional genetic or epigenetic changes are necessary for progression to metastasis, as distinct from initiation of sarcomagenesis (Przybyl et al., 2014; Jones et al., 2016).

One of the most frequent secondary genetic changes demonstrated in human SS is loss of the phosphatase and tensin homologue on chromosome 10 (PTEN) gene (Barretina et al., 2010). The negative regulator of phosphatidylinositol 3′-lipid (PI3′-lipid) signaling, PTEN is a tumor suppressor gene that is frequently silenced or lost in many cancer types (Ali et al., 1999; Vivanco and Sawyers, 2002; Oda et al., 2005; Zbuk and Eng, 2007; Chalhoub and Baker, 2009). The resultant increase in PI3′-lipid signaling leads, among many effects, to phosphorylation and activation of protein kinase B (termed pAKT), which results in a variety of downstream signaling that encourages proliferation and prevents apoptosis (Tamura et al., 1998; Patel et al., 2001; Chow and Baker, 2006).

Loss of PTEN associates with tumor aggressiveness and progression to metastasis in some cancers (Depowski et al., 2001; Decopoulos et al., 2003; Vasudevan et al., 2009; Kim et al., 2015). Such a relationship has not been shown specifically in SS, but increased PI3′-lipid signaling correlates with a worse prognosis in this disease (Friedrichs et al., 2011; Setsu et al., 2013). As a result of the many and pleiotropic effects of loss of PTEN, especially when interwoven into genetically complex cancers, such as melanoma and carcinomas of the lung, prostate, and breast, the precise contribution of PTEN loss...
to oncogenesis can be difficult to decipher (Oda et al., 2005; Stemke-Hale et al., 2008; Chalhoub and Baker, 2009). We therefore determined to test the impact of Pten silencing in the genetic mouse model of SS, in the hope that it could provide tractable information with regard to the biology of PI3'-lipid signaling in the progression of solid tumor malignancies.

RESULTS
Pten silencing enhances synovial sarcomagenesis in the mouse
To test the impact of Pten silencing in SS, mice bearing conditional expression alleles of SS18-SSX1 (hSS1) or SS18-SSX2 (hSS2) were bred to mice bearing a conditional disruption allele of Pten (Fig. 1 A). Tumorigenesis was initiated in mice of each genotype by the injection of TATCre, which was previously shown to induce synovial sarcomagenesis from activation of hSS1 or hSS2 in a majority of mice, but only after a long latency (Barrott et al., 2015; Jones et al., 2016).

The addition of homozygous conditional silencing of Pten was sufficient to decrease the latency to tumorigenesis and increase the prevalence of tumorigenesis to full penetrance when combined with expression of either SS fusion gene (Fig. 1 B). A control group with TATCre-induced
homzygous silencing of Pten alone developed no tumors by 600 d after injection. The tumors that developed from activation of hSS1 or hSS2 and Pten silencing were compared with mouse tumors from TATCre-activated hSS1 or hSS2 alone, as well as to human SSs. Pten silencing did not change the development of the classic histological features of SS in the mouse tumors (Fig. 1 C and Fig. S1 A). These features included biphasic histology, wherein cells of both mesenchymal and epithelial characteristics and morphology intermingle and the latter even coalesce into glandular structures. As the development of these features requires a full reprogramming of germ-layer-derived cellular identity, it is considered a hallmark of SS and is pathognomonic for the disease. The ratio of biphasic to monophasic (only mesenchymal-character cells) histology did not differ between Pten-proficient and -deficient sarcomas. Immunohistochemical stains, used to make the histological diagnosis of SS clinically, also demonstrated classic patterns, regardless of Pten silencing (Fig. 1 D and Fig. S1 B). Thus, PTEN deficiency accelerated and enhanced fusion-initiated synovial sarcomagenesis in the mouse.

**Pten silencing promotes pulmonary metastasis from mouse synovial sarcoma**

In contrast to virally delivered Cre-recombinase expression vectors, which have potential for systemic escape from the localized injection, distribution to a distant site, cell infection, and Cre-mediated recombination, the injection of TATCre is more confidently localized in its Cre-mediated recombination effect. Because multiple Cre-recombinase proteins are required in each cell to mediate the recombination events, the likelihood that systemic escape of a few injected protein molecules will result in distant recombination events is vanishingly small. TATCre induction also differs meaningfully from Cre-expression from any promoter, either transgenic or targeted in the mouse genome, where multiple anatomical sites of disease are initiated simultaneously or metachronously, reducing the opportunity to clarify primary versus metastatic sites of sarcoma. TATCre induced tumorigenesis therefore offered a unique opportunity to test for true metastasis in this model.

Mice of each Pten genotype were assessed for the development of metastatic foci of SS, initially by gross dissection. Approximately 44% of the hSS1;Pten<sup>fl/fl</sup> and hSS2;Pten<sup>fl/fl</sup> mice had grossly apparent pulmonary metastatic disease, but only 1 out of 10 of the Pten-wildtype comparators had apparent metastasis (Fig. 2 A and B), that in a mouse aged to nearly 2 yr. Histological sectioning of the pulmonary parenchyma confirmed the same (Fig. 2 C). Histology expanded the number of metastatic foci identified per mouse, as well as the prevalence of hSS;Pten<sup>fl/fl</sup> mice (but neither hSS1 nor hSS2 alone) with any metastasis, which approached 70% (Fig. 2 D). Immunohistochemical staining against GFP, which is expressed with the fusion gene from an internal ribosomal entry site that is present on both the hSS1 and hSS2 alleles, enabled definitive confirmation not only of the tumor-identity of the metastatic cells, but also their expression of the fusion oncogene (Fig. 2 E).

To determine whether Pten silencing enabled greater tumor cell dissemination to the lungs or simply greater growth after dissemination, we developed a PCR assay to detect a recombined genomic DNA segment in the Ros<sup>26</sup> locus that would only be present in tumor cells disseminated to the lung. This assay was used to test lung tissue for disseminated tumor cells in mice of each Pten genotype that had developed tumors, but no grossly or histologically detectable metastasis. Many of the lungs of Pten-silenced hSS1 or hSS2 mice without ostensible metastatic foci (detectable by gross dissection or histological assessment) demonstrated the presence of disseminated tumor cells by PCR (Fig. 2 F). Lungs of mice with PTEN-proficient sarcomas did not. This increased the estimated fraction of hSS;Pten<sup>fl/fl</sup> mice with evidence of disseminated tumor cells in the pulmonary parenchyma by the time of sacrifice as a result of morbidity to >90% (Fig. 2 G). This suggests that Pten silencing specifically promoted sarcoma cell dissemination.

**Metastatic synovial sarcomas were more vascular but otherwise indistinct**

Clinically, risk of sarcoma metastasis correlates with primary tumor size, as well as loosely with time between tumor development and treatment initiation. Primary tumor size did not differ significantly between tumors of each genotype at the time of the morbidity-driven host euthanasia and tumor harvest (P = 0.12). Primary tumor size also did not correlate with detectable metastasis in Pten-silenced tumors (P = 0.51). Age at sacrifice only trended toward older ages for mice of the Pten<sup>fl/fl</sup>;hSS1 and Pten<sup>fl/fl</sup>;hSS2 genotypes that developed grossly or histologically detectable metastasis compared with those that did not (P = 0.14; Fig. 3 A).

Theoretical models for the metastasis of solid tumor cells to distant sites typically involve strengthening of the cancer hallmarks of proliferation, angiogenesis, metabolism, and invasion, often characterized in epithelial-derived carcinomas by a transition to a mesenchymal state or the development of necrosis. We therefore compared each of these parameters between primary tumors with wild-type Pten, primary tumors with silenced Pten, and metastatic tumors of the latter genotype. Ratios of monophasic and biphasic (more epithelial) histology did not differ between the tumor groups. Additionally, the epithelial histology was retained in many of the metastatic foci from epithelial primary tumors (Fig. 3, B–D; and Fig. S2 A).

Ki-67 proliferative indices did not differ between PTEN-proficient versus -deficient sarcomas (Fig. 3 E). To answer the question whether increased necrosis correlated with PTEN deficiency, and thus could contribute to metastatic potential, we measured percent necrosis between the two Pten genotypes and found no significant difference.
Although SS is considered a strongly angiogenic tumor, with characteristic hemangiopericytomatosous vascular patterns as one of the diagnostic features, Pten silencing increased the vascularity of primary tumors significantly (Fig. 3 G). This increased density of vessels was less pronounced in small metastatic foci, but increased relative to cross-sectional area in larger metastases (Fig. 3 H and Fig. S2 B), suggesting that environmental signals or oxygen tension can yet impact angiogenesis, rather than an exclusive cell-intrinsic impact of Pten silencing alone.
**Pten silencing drives an inflammatory transcriptome in mouse synovial sarcomas**

To compare the transcriptional impact of PTEN deficiency on SS, we sequenced total RNA from tumors initiated by TATCre-induced hSS1 or hSS2 and either wild-type or homozygous floxed Pten. The transcriptomes of tumors grouped by Pten genotype demonstrated differential expression of 4,051 genes with an absolute log2 ratio > 1 and adjusted P < 0.05 significance level (Fig. 4 A and Table S1). Unbiased ingenuity pathway analysis of these differentially expressed genes identified inflammatory pathways and inflammatory upstream regulators as the top hits (Fig. 4 B and Table S2).

In detail, PTEN-deficient sarcomas demonstrated increased inflammation-related gene transcription. Especially increased was the expression of inflammatory recruiting signals and their receptors: Ccl7 and Ccl11 with Ccr3, Xcl1 with Xcr1, and CSF1 with CSF1R (Fig. 4 C).

We also compared transcriptomes between primary tumors and their associated metastases. Each metastasis clustered tightly with its primary tumor (Fig. 4 D), suggesting that SS tumors harbor minimal intratumoral heterogeneity from which sub-clones metastasize, and that even very distinct environments (the limb versus the lung) minimally impact the whole-tumor transcriptome. Metastatic tumors also demon-
strated inflammatory transcriptomes, but not as pronounced as their related primary tumors (Tables S3 and S4).

**Pten silencing increases myeloid-derived cell infiltration into synovial sarcomas**

Suspecting that tumor cells were not independently responsible for the inflammatory gene expression patterns, we analyzed tumors of each genotype by flow cytometry. The three cell subtypes that were most dramatically increased were two subsets of F4/80+ cells, Ly6C<sup>mide</sup>MHC-II<sup>+</sup> cells and Ly6C<sup>hi</sup>MHC-II<sup>+</sup> cells, and Ly6C<sup>+</sup>Ly6G<sup>+</sup> cells, representing macrophages, monocytes, and neutrophils, respectively (Fig. 5A and Fig. S3A). Specifically within the non-GFP population, the myeloid cell fraction (CD11b<sup>+</sup>) increased fivefold in PTEN-deficient sarcomas (Fig. 5B and Fig. S3B).

Tissue sections from tumors of each genotype were also assessed by anti-CD68 immunohistochemistry. This confirmed increased macrophages/monocytes in tumors of the Pten<sup>p<sub>fl/fl</sub></sup>;hSS genotypes (Fig. 5C). Neutrophils were assessed using Leder cytochemical staining for the granulocytic lineage, which demonstrated higher prevalence in PTEN-deficient tumors (Fig. 5D). To evaluate the presence of lymphocytic infiltrates as a contributing factor to the inflammatory phenotype, tumors from each genotype were immunohistochemically stained with anti-CD3, which resulted in low (0.5 ± 0.1%; mean ± SEM) yet similar numbers of CD3<sup>+</sup> cells in Pten-silenced and Pten-wild-type tumors (Fig. 5E).

Evaluation of peripheral blood counts demonstrated elevated neutrophil fractions of leukocytes (Fig. 5F), as well as increased neutrophil counts in mice growing PTEN-deficient tumors (Fig. 5G).

**Mouse synovial sarcoma cells with added Pten silencing express Csf1**

To determine the specific cellular sources of the abundant myeloid recruiting signals and receptors apparent in the whole-tumor transcriptomes of Pten-silenced and SS18-SSX–expressing mouse sarcomas, freshly harvested tumors were dissociated and sorted by flow cytometry into GFP<sup>+</sup> (and therefore SS18-SSX-expressing) tumor cells, macrophages, and neutrophils (Fig. 5A and Fig. S3A). Because FACS preparation of fresh tumor samples requires multiple hours of dissociation and labeling, we did not anticipate that it would render accurate quantitative transcriptional levels of genes, but merely expression relative to the other cell fractions to enable identification of the principal source cell fraction for each gene’s transcripts. Total RNA isolated from each cell fraction was subjected to NanoString analysis, using the inflammatory mediator panel. As proof of the assay’s validity as a test of cell fraction relative expression, four genes consid-
Figure 5. *Pten* silencing associates with increased infiltration of myeloid-derived cells. (A) Example flow cytometry comparing an *hSS;Pten*<sup>+/+</sup> tumor (top) to an *hSS;Pten*<sup>−/−</sup> tumor (bottom) for F4/80<sup>+</sup>/GFP<sup>−</sup> monocytes/macrophages (arrowhead, left plot), their MHCII<sup>+</sup>/Ly6C<sup>+/-</sup> newly recruited monocyte (open arrow, middle plot) and MHCII<sup>+</sup>/Ly6C<sup>−</sup> tissue macrophage (filled arrowhead, middle plot) subpopulations, and Ly6C<sup>+</sup>/Ly6G<sup>−</sup> neutrophils (arrowhead, right plot). (PE, phycoerythrin; APC, allophycocyanin; PerCP, peridinin chlorophyll protein). (B) Graph comparing the percent of infiltrating CD11B<sup>+</sup> cells in *hSS* tumors of each *Pten* genotype (Student’s t test). (C) Representative low and high power photomicrographs and quantitation of CD68<sup>+</sup> monocytes/macrophages (brown) by immunohistochemistry in *hSS;Pten*<sup>+/+</sup> and *hSS;Pten*<sup>−/−</sup> tumors (Student’s t test). (D) Representative low and high power photomicrographs and quantitation per high power field (HPF) of Leder cytochemically stained neutrophils (magenta) in *hSS;Pten*<sup>+/+</sup> and *hSS;Pten*<sup>−/−</sup> tumors (Student’s t test). (E) Representative photomicrographs of CD3 immunohistochemistry in *hSS;Pten*<sup>+/+</sup> and *hSS;Pten*<sup>−/−</sup> primary tumors and an associated graph demonstrating low and equivalent numbers of CD3<sup>+</sup> lymphocytes (Student’s t test). (F) Pie charts presenting the mean fractions of neutrophils, monocytes, and lymphocytes in the peripheral blood of morbid tumor-bearing *hSS;Pten*<sup>+/+</sup> and *hSS;Pten*<sup>−/−</sup> mice (n = 7 and 13, respectively; Chi-squared test). (G) Graph of peripheral blood neutrophil counts in morbid tumor-bearing *hSS;Pten*<sup>+/+</sup> and *hSS;Pten*<sup>−/−</sup> mice (Student’s t test). Bars, 50 µm. Graph points present individual tumors; bars present means.
erated markers of each cell fraction (i.e., SS tumor cells, macrophages, and neutrophils) demonstrated elevated expression in the index cell fraction (Fig. 6 A). The normalized expression data for myeloid recruitment ligand/receptor pairs (Fig. 6 B) were then multiplied by the numerical fraction of each cell type by flow analysis to render an estimated percentage of the overall transcripts in the whole tumor that came from each cell type (Fig. 6 C and Table S5).

Of five potential macrophage chemoattractant receptors, Csf1r, Ccr2, Cx3cr1, Cxcr4, and Cxcr2, the estimated expression percentages of all but the last were highest in macrophages. The largest percentage of Cxcr2 expression came from neutrophils. Tumor cells were the most prominent source of the matched, recruiting ligands Csf1, Ccl2, Cx3cl1, Cxcl2, and Cxcl1. However, in our whole-tumor RNAseq data (Fig. 6 D), only the first two were significantly up-regulated in tumors with silenced Pten compared with wild-type Pten. This suggests that Pten-silenced tumor cells expressing Csf1 and/or Ccl2 recruit macrophages expressing Csf1r and Ccr2. Although tumor cells also expressed high levels of Cxcl12, which can recruit Cxcr4-expressing macrophages, this expression cannot explain the increased infiltrating macrophages associated with Pten-silencing, because Pten-wild-type tumors also expressed high levels of this recruiting ligand (Fig. 6 D). Macrophages were the greatest source cell fraction for the other potential ligands for Ccr2, suggesting the presence of auto-recruitment signals in addition to the tumor-expressed recruitment by Ccl2 and Csf1 (Fig. 6, B–D).

Immunohistochemistry demonstrated macrophages with phosphorylated CSF1R, which indicates ligand activation, in Pten-deficient tumor sections (Fig. 6 E). These pCSF1R+ cells were typically in close proximity to tumor cells, not neutrophils, further suggesting that tumor cells drive monocytic lineage recruitment to the tumor microenvironment. However, macrophages were not the only cell fraction affected by tumor secreted CSF1, as activated pCSF1R was detected in endothelial cells as well (Fig. 6 E). Macrophages were the dominant, nonautocrine, source cell fraction for the expression of the systemic neutrophil stimulant Il1b (Fig. 6, F–H).

To evaluate if inhibition of CSF1 signaling reduces the recruitment of macrophages in PTEN-deficient SSs, we treated mice for 3 wk with a potent and selective inhibitor of CSF1R, BLZ945 (Pyonteck et al., 2013). As indicated by flow cytometry analysis for F4/80+ macrophages and immunohistochemical analysis for CD68+ macrophages, inhibition of CSF1R reduced their presence in dissociated tumors and FFPE tumors (Fig. 6, I and J). BLZ945 at 200 mg/kg also limited tumor volume growth compared with a twofold increase in the control-treated mice (Fig. 6, K and L).

**PI3′-lipid signaling in synovial sarcomas drives CSF1 expression**

To confirm Pten silencing in the tumors that arose after TAT-Cre injection into hSS;PtenΔ/Δ mice, we isolated whole tumor protein lysates and performed Western blots. These demonstrated the absence of PTEN and strong increases in pAKT, but not total AKT, compared with Pten-wild-type tumors (Fig. 7 A). Immunohistochemistry against pAKT verified this result at the tissue level (Fig. 7 B and Fig. S4 A).

To assess the broader relationship between increased PI3′-lipid signaling and myeloid chemoattractant expression, we transfected an active mutant (H1047R) of PIK3CA into two human SS cell lines. SYO1 expresses SS18-SSX2. Yamato-SS expresses SS18-SSX1. Compared with empty vector transfections, each cell line increased pAKT levels and increased CSF1 expression by RT-qPCR. This effect was blocked by the application of 5 μM LY294002, a pan-PI3′-lipid kinase inhibitor (Fig. 7, C and D).

Although it lacks the superior pharmacokinetics of developed drugs, LY294002 has also demonstrated PI3′-lipid kinase inhibition in vivo (Semba et al., 2002). To test the dependence of chemoattractant signal expression on PI3′-lipid signaling in vivo, PtenΔ/Δ;hSS mice with large tumors were randomized to daily oral gavage administration of LY294002 or vehicle control for 1 wk before tumor harvest. Westerns and immunohistochemistry demonstrated only modest reductions in pAKT (Fig. 7 E and Fig. S4 B), confirming our anticipation that LY294002 was not likely to demonstrate serious tumor-impacting PI3′-lipid inhibition. The hypothesized impact on Csf1 expression; however, was confirmed (Fig. 7 F). Further, tumor infiltrating CD11b+ by flow cytometry and Leder-stained neutrophil counts on histological sections were also reduced after LY294002 administration compared with vehicle control treatment (Fig. 7, G and H).

As a result of the short duration of treatment, there was no expectation that treatment would significantly affect the primary tumors and large lung metastases. Nevertheless, it was expedient to assay the disseminated tumor cells in the circulation to see if LY294002 treatments decreased the presence of these cells in the blood. Indeed, we observed by digital droplet PCR (ddPCR) the presence of the recombined Rosa26 locus in the lungs and blood of control-treated animals. The ratio of lung/blood tumor DNA was reduced significantly in the LY294002-treated samples (Fig. 7, I and J).

**Tumor-associated neutrophils and monocytes correlate with PI3′-lipid signaling in SS**

Silencing of Pten in the mouse tumors primarily represents an experimental in vivo boost to PI3′-lipid signaling. PI3′-lipid signaling may be increased in human SS through a variety of other means. We therefore tested the more general relationship between pAKT presence, as a common marker of PI3′-lipid signaling, and infiltrating myeloid-derived cells in a large panel of human SS on a tissue microarray (TMA). With 382 samples from 191 human SSs, we screened cases for pAKT by immunohistochemistry, identifying 4.7% negative, 34% low, 36.6% intermediate, and 24.6% high for expression of pAKT (Fig. 8 A). Human SSs were grouped into the different levels of pAKT and correlative stains of pCSF1R and...
Figure 6. *Pten* silencing enhanced synovial sarcoma cells express Csf1. (A) NanoString expression graphs of marker genes for each cellular fraction from whole *hSS;Pten<sup>w/w</sup>* tumors, with expression normalized to that in each index cell type (MΦ, macrophage; PMN, polymorphonuclear cell or neutrophil). (B) NanoString expression levels heat map of macrophage recruitment receptors and their corresponding ligands in each source cell fraction of tumors. (C) Heat map of the estimated (est.) percent contribution to each gene's overall expression in the tumor from each source cell fraction, generated by normalizing the NanoString expression by the mean numerical fraction of cells. (D) Heat map of the mean log<sub>2</sub>-transformed FPKM expression level for each gene in *hSS;Pten<sup>w/w</sup>* and *hSS;Pten<sup>fl/fl</sup>* tumors. *, *P < 0.05. (E) Photomicrograph of immunohistochemistry with an anti-pCSF1R antibody, demonstrating macrophages (left) and endothelial cells (right) in a tumor section actively receiving and transducing CSF1 signal. Bar, 10 µm. (F–H) Heat maps as in B–D, but of neutrophil stimulants. Notably, G-CSF (Csf3) and GM-CSF (Csf2) were not significantly expressed by tumors in whole transcriptome profiling, with or without Pten silencing. (I) Graph comparing the percent macrophage population in control tumors or tumors treated with BLZ945. Statistical test did not include outlier in control with high percentage of macrophage (Student's t test). (J) Representative flow cytometry demonstrating a decreased population of macrophages in the BLZ945-treated tumors (bottom) compared with control (top). Photomicrograph of immunohistochemistry with an anti-CD68 antibody, showing a decrease in macrophages in BLZ945 treated tumors (bottom) compared with control (top). (K) Graph of percent tumor growth over baseline for 21 d of treatment with or without 200 mg/kg of BLZ945. *, *P < 0.05; **, *P < 0.01. n = 5 per group, Student's t test. (L) Examples of photomicrographs of control tumors and BLZ945-treated tumors with corresponding GFP expression demonstrating the twofold increase in control tumor volume. Middle panel is control lungs with grossly visible metastases (arrowheads). Bars: (black) 10 µm; (white) 5 mm.
Figure 7. PI3′-lipid signaling drives CSF1 expression in synovial sarcoma. (A) Representative Westerns for PTEN, pAKT, and AKT in hSS;Pten<sup>fl/fl</sup> and hSS;Pten<sup>−/−</sup> tumors, with quantitation from four tumors from each. Performed independently four times with eight different hSS;Pten<sup>fl/fl</sup> tumors and four different hSS;Pten<sup>−/−</sup> tumors (Student’s t test). (B) Representative photomicrographs of pAKT immunohistochemistry in hSS;Pten<sup>fl/fl</sup> and hSS;Pten<sup>−/−</sup> tumors. (C) Westerns for pAKT and AKT from two human SS cell lines transfected with empty vector (pBabe), wild-type PIK3CA, or constitutively active mutant PIK3CA (H1047R). Performed independently three times. (D) Graph of RT-qPCR expression of CSF1 in cell lines transfected with empty vector, wild-type PIK3CA, or constitutively active mutant PIK3CA (H1047R) with or without PI3′-lipid kinase inhibition with LY294002 (noted as LY). Performed independently at least

- Barrott et al. (2017) JEM
Leder cytochemical stains were performed in blinded fashion. Mean scores per human tumor were plotted against pAKT. All three comparisons demonstrated correlation coefficients >0.79 and ANOVA showed a statistically significant difference across samples in the pAKT and pCSF1R comparison (P < 3 × 10⁻⁶; Fig. 8 B).

**DISCUSSION**

Others have previously demonstrated diverse facets of PI3′-lipid signaling in SS. By transcriptome profiling, many human SSs express receptor tyrosine kinases and their corresponding ligands, such as PDGFRα and PDGFrα (Tamborini et al., 2004), FGFRs and FGFs (Ishibe et al., 2005), or EGFR and EGF (Nielsen et al., 2002; Blay et al., 2004; Thomas et al., 2005; Teng et al., 2011). There is evidence for epigenetic down-regulation of PTEN in many human SS cell lines (Su et al., 2010), which have also shown PI3′-lipid activity by pAKT levels and the inhibition of pAKT and proliferation with the PI3′-lipid kinase inhibitor LY294002 (Friedrichs et al., 2011). Immunohistochemistry on human tumor samples has also shown a correlation between pAKT and poor prognosis, including development of metastatic disease (Setsu et al., 2013). Although PTEN loss, PIK3CA-activating mutations, RAS-activating mutations, and other genetic means of increasing PI3′-lipid signaling have each been identified in only a small minority of human SSs (Barretina et al., 2010), we used one of these to effect a material change in the metastatic potential of SS18–SSX-driven tumors in mice. Alternatively, increased PI3′-lipid signaling might be achieved through the full range of upstream signaling, in many human SSs that progress. Importantly, the PI3′-lipid alterations in this model were tumor cell–intrinsic, distinct from any myeloid cell PI3′-lipid signaling.

Several other mouse genetic models of cancer have demonstrated increased metastasis upon the addition of Pten silencing (Stambolic et al., 2000; Abate-Shen et al., 2003; Wang et al., 2003; Knobbe et al., 2008). In most of these, an already apparent metastatic phenotype was enhanced by the silencing of Pten. The clarity of the phenotype in the genetically simple model of synovial sarcomagenesis certainly presents an opportunity for deeper study of the means by which PI3′-lipid signaling enables metastasis in future investigation. We have shown already that Pten silencing–mediated proliferation alone has not enabled this phenotype by mere outgrowth of already disseminated cells. Other than the one metastatic tumor in a single, 2-yr-old mouse, Pten-wild-type tumors had no evidence of even disseminated cells by PCR. Further, another model with the addition of β-catenin stabilization to SS18–SSX2 expression grew even faster than tumors enhanced by Pten silencing, but did not exhibit the prevalent metastatic phenotype (Barrott et al., 2015). The effects of PI3′-lipid signaling in a tumor cell are pleiotropic, including growth, survival, proliferation, apoptosis, cell migration, inflammation, and metabolism (Chalhoub and Baker, 2009). The contribution of each may participate in metastasis.

Among these, inflammation has particularly been linked to PTEN absence. Increased inflammation has been identified in models of Pb-Cre+;Ptenlox/lox prostate cancer (Maxwell et al., 2013; Garcia et al., 2014) Pten−/−;p53−/− breast cancer (Kim et al., 2015), and Dct::TVA;BrafCA;Cdkn2alox/lox melanoma (Cho et al., 2015), as well as in human samples of breast cancer (Lin et al., 2002) and squamous cell carcinomas of the head and neck (Young and Lathers, 1999) associated with PTEN loss. The mechanism for this PI3′-lipid–related inflammation and metastasis has been somewhat elusive, and generally attributed to increased growth rates, increased necrosis, or genetic instability driving the creation of neo-antigens. One study linked xenograft breast metastasis to IL-6–mediated inflammatory signaling in a Pten/Trp53-null background. However, there was no connection to inflammatory cell recruitment as a result of the NOD/SCID mouse background (Kim et al., 2015). A study of UV-induced melanoma showed that an inflammatory response promoted angiogenesis, melanocyte migration, and neutrophil recruitment (Bald et al., 2014), but the inflammatory response was attributed to cell–extrinsic factors rather than the tumor cells themselves. In the SS mice and in human cell lines and tumor samples, we have linked Csf1/CSF1 expression to increased PI3′-lipid signaling and found this to be a manipulable program for myeloid recruitment.

The role of these inflammatory cells in either suppressing or supporting metastasis will also be the subject of intensive future investigation. Both relationships have been demonstrated in other model systems. Studies in human leiomyosarcoma have associated macrophage recruitment to high CSF1 expression in the sarcoma, which correlates to a worse prognosis (Lee et al., 2008; Espinosa et al., 2009). In the inflammation-associated melanoma model, neutrophil recruitment promotes tumor–endothelial interactions in the lungs to promote seeding (Huh et al., 2010; Cools-Lartigue et al., 2011).

three times [Student's t test]. (E) Graph of the mean ± SE of the pAKT suppression (not significant) in hSS;Ptenfl/fl tumors treated in vivo for 1 wk with 70 mg/kg body mass LY294002 or vehicle control [Student's t test]. (F) Graph of the reduced Csf1 expression by RT-qPCR in hSS;Ptenfl/fl tumors treated in vivo for 1 wk with LY294002 or control [Student's t test]. (G) Graph of the percent CD11B+ cells by flow cytometry in hSS;Ptenfl/fl tumors treated in vivo for 1 wk with LY294002 or control (Student's t test). (H) Graph of the neutrophil counts by Leder stain in tissue sections from hSS;Ptenfl/fl tumors treated in vivo for 1 wk with LY294002 or control (Student's t test).
We observed in the SS model the presence of some aspects of described prometastatic roles for myeloid inflammatory cells (Gabrilovich, 2015). The mouse tumor cells express Ccl2, which has been described as a means of communication between tumor cells and monocytes that enables metastasis (Bonapace et al., 2014). Also, the SS tumor–associated macrophages demonstrated high expression of IL-1β, the systemic effects of which were evident in peripheral blood neutrophil counts. This signaling, through γδT cells at distant sites, has been shown to enable neutrophil-mediated metastasis (Coffelt et al., 2015). The complexity of these relationships may be optimally tested in this new model, especially considering that most other models depend on engrafted tumor cell lines or dissemination of tumor cell lines by embolization in the pulmonary parenchyma in mice with altered immune systems.

Herein, we have not demonstrated any specific, driving role for tumor–associated inflammatory cells in the aggressiveness of this mouse model of SS. Nevertheless, the association between inflammation and SS metastasis encourages...
the prospect of pharmacologically targeting inflammatory cells to impact the tumor cells indirectly. Already, strategies are being investigated in other disease models with cautious enthusiasm. Vaccines that specifically target tumor-associated macrophages in colon, breast, and lung carcinoma metastases have reduced both tumor volumes and macrophage numbers (Luo et al., 2006). Likewise clodronate liposomal depletion showed promising results in models of lung carcinoma (Fritz et al., 2014). Targeting CSF1R and CCR2 with small molecule inhibitors or monoclonal antibodies in pancreatic and breast carcinomas depleted macrophages, which resulted in deleterious effects on the tumors (DeNardo et al., 2011; Mitchem et al., 2013; Ries et al., 2014). Most of the tumor cytoreduction using these strategies was attributed to loss of modulation of the lymphocytic T cell response. SS presents an ideal opportunity to interrogate potentially targetable roles for inflammation distinct from T cell modulation.

As a result of the genetic simplicity of the SS mouse model with Pten conditional ablation alleles and working with a fully competent immune system, we may begin to unravel the complexities of PI3′′-lipid signaling that result with a fully competent immune system, we may begin to unravel the complexities of PI3′′-lipid signaling that result with a fully competent immune system, we may begin to unravel the complexities of PI3′′-lipid signaling that result.
ish peroxidase detection methods and counterstained with hematoxylin. The complete list of antibodies can be found in Table S7. Leder staining with Naphthol AS-D chloroacetate esterase (Sigma-Aldrich) was performed per manufacturer recommendations.

Flow cytometry
Specimens were minced, enzymatically digested (Tumor Dissociation kit; Miltenyi Biotec), and mechanically dissociated (GentleMACS Tissue Homogenizer; Miltenyi Biotec). Tissue debris was removed using 70-µm MACS Smart strainers (Miltenyi Biotec). Cells from all tissues were washed with PBS containing 0.5 mg/ml bovine serum albumin, and then stained using a cocktail of rat anti–mouse antibodies from BD: Ly6C, CD11b, I-A/1-E, F4/80, Ly-6G, and DAPI (Invitrogen). Cell expression was determined by multicolor flow cytometry on a FACSCanto flow cytometer (BD) and cell sorting was performed using a FACSaria (BD) and FlowJo 8.7.1 (Tree Star) for analysis.

Immunoblotting
Protein was isolated using a mild lysis buffer (10 mM Tris-HCl, pH 8.1, 10 mM NaCl, 0.5% NP-40, and protease inhibitors), clarified by centrifugation, loaded at 25 µg/sample for gel electrophoresis, and then transferred to PVDF membranes. Western blots were detected with goat anti–rabbit secondary antibodies and horseradish peroxidase.

Digital droplet PCR
DNA was isolated from tumor, lung, and blood tissues using the DNeasy kit (QIAGEN). 25 ng of DNA was analyzed using primers that amplified the recombined Rosa26 locus, following the manufacturer’s recommendations for emulsification in a QX200 droplet generator, thermocycling on a C1000, and analysis using QuantaSoft software (all from Bio-Rad Laboratories).

Statistical methods
For most comparisons between PTEN-proficient and -deficient sarcomas, a two-tailed Student’s t test was performed. All sample sizes are stated in the figure legends unless each data point is plotted in the figure. Statistical significance for the Kaplan Meier plots was determined by using a log-rank test. Ingenuity pathway analyses used a right tailed Fisher Exact Test and Benjamini-Hochberg correction for multiple testing. Pie chart percentage comparisons were tested using a χ² test. In the tissue microarray, the mean values of pCSF1R IHC and Leder stain were plotted against pAKT IHC and linear regression correlation was calculated with the R² values being provided. A single-factor ANOVA was also performed on pCSF1R values between the different pAKT bins. All counting and scoring was performed under reader blinding.

Accession no.
Raw RNA sequencing data are available from NCBI GEO under accession no. GSE81476.

Online supplemental material
Fig. S1 shows Pten disruption enhances synovial sarcoma genesis. Fig. S2 shows lung metastases retain primary tumor histology and E-cadherin expression and increases in vascularity with size. Fig. S3 shows Pten disruption associates with increased infiltration of myeloid-derived cells. Fig. S4 shows PI3′-lipid signaling drives phosphorylation of AKT and downstream expression of CSF1. Table S1 lists differential gene expression between Pten<sup>+/−</sup> and Pten<sup>−/−</sup> synovial sarcomas. Table S2 lists ingenuity pathway analysis of potential upstream regulators between Pten<sup>+/−</sup> and Pten<sup>−/−</sup>. Table S3 lists differential gene expression between primary and lung metastases Pten<sup>−/−</sup> synovial sarcomas. Table S4 lists Ingenuity pathway analysis for potential upstream regulators between primary and lung metastases Pten<sup>−/−</sup> synovial sarcomas. Table S5 Nanostring gene expression on sorted cell populations with normalized values based on prevalence in flow cytometry. Tables S1–S5 are available as Excel files. Tables S6 lists specific antibodies used, and Table S7 lists specific primers used.

ACKNOWLEDGMENTS
The authors thank Sheri Holmen of Huntsman Cancer Institute for sharing wisdom and the Pten−/−mouse strain. The authors gratefully received histology technical assistance from Sheryl Tripp at ARUP laboratories and Blake Anderson at Huntsman Cancer Institute Histology Core, RNA sequencing and NanoString assistance from Brian Dalley and John O’Shea at the Huntsman Cancer Institute Genomics core, digital droplet PCR assistance from Brian Whitmire and Hector Macias-Saldivar at Bio-Rad Laboratories, Heska training from Tony Pomicter of the Deininger laboratory at Huntsman Cancer Institute, and Flow cytometry assistance from James Marvin and Chris Leukel at the University of Utah Flow Cytometry core. The Paul Nabil Bustany Memorial Fund for Synovial Sarcoma Research, the Sarcoma Cancer Foundation of Canada (Beth England’s Sarcoma Research Fund), and the Damon Runyon Cancer Research Foundation provided funding for this project. This work was also partly supported by National Cancer Institute award P30CA042014. Work in the University of Utah Flow Cytometry Facility was also supported by the National Center for Research Resources of National Institutes of Health, 1S10RR026802-01.

The authors declare no competing financial interests.

Author contributions: J.J. Barrott and K.B. Jones conceived the idea, designed experiments, and wrote the manuscript. J.J. Barrott, L.A. Kafchinski, H. Jin, S.D. Kannan, and R. Kennedy carried out experiments. T. Mosbruger performed bioinformatics on RNAseq and NanoString data and generated heat maps and clustering figures. A.J. Lazar and T. Liu provided the histopathological review, and A.J. Lazar, W.-L. Wang, J.-W. Tsai, and D.M. Araujo generated the human tissue microarray. All authors reviewed and edited the manuscript.
REFERENCES
Primary tumours modulate innate immune signalling to create pre-metastatic vascular hyperpermeability foci. Nat. Commun. 4:1853. http://dx.doi.org/10.1038/ncomms2856


SUPPLEMENTAL MATERIAL

Barrott et al., https://dx.doi.org/10.1084/jem.20160817

Figure S1. 

***Pten disruption enhances synovial sarcomagenesis.*** (A) Photomicrographs of H&E histology demonstrating the range of mesenchymal and epithelial characteristics in SS18-SSX–induced synovial sarcomas from each Pten genotype in TATCre–injected mice. (B) Photomicrographs after immunohistochemistry on hSS/Pten+/− tumor tissue sections with noted primary antibodies, demonstrating characteristic SS staining patterns. Bars, 25 µm.
Figure S2. **Lung metastases retain primary tumor histology and E-cadherin expression and increases in vascularity with size.** (A) Photomicrographs of tumors with retained histological appearance between primary tumor and metastasis. (B) Examples of anti-CD31 immunohistochemistry photomicrographs demonstrating vascular density in hSS;Pten lung metastases. Bars, 100 µm.
Pten disruption associates with increased infiltration of myeloid-derived cells. (A) Example flow cytometry comparing an hSS;Pten<sup>−/−</sup> tumor (top) to an hSS;Pten<sup>fl/fl</sup> tumor (bottom) for showing the hierarchal gates used for sorting F4/80<sup>+</sup>/GFP<sup>−</sup> monocytes/macrophages (sixth plot), their MHC II<sup>+</sup>/Ly6C<sup>high</sup> newly recruited monocyte (seventh) and MHC II<sup>+</sup>/Ly6C<sup>mid</sup> tissue macrophage (seventh plot) subpopulations, and Ly6C<sup>+</sup>/Ly6G<sup>+</sup> neutrophils (fifth plot). (B) Examples of CD11b<sup>+</sup> flow cytometry comparing hSS;Pten<sup>−/−</sup> tumors (top) to hSS;Pten<sup>fl/fl</sup> tumors (bottom). Current display demonstrates Ly6C<sup>+</sup>/Ly6G<sup>+</sup> neutrophils, Ly6C<sup>high</sup>/Ly6G<sup>−</sup> monocytes, and Ly6C<sup>mid</sup>/Ly6G<sup>−</sup> macrophages.
Figure S4. PI3′-lipid signaling drives phosphorylation of AKT and downstream expression of CSF1. (A) Representative photomicrographs of pAKT immunohistochemistry in hSS;Pten"w/w and hSS;Pten"fl/fl primary tumors (left) and hSS;Pten"fl/fl lung metastasis (right). (B) Representative photomicrographs of pAKT immunohistochemistry in hSS;Pten"fl/fl primary tumors after 1-wk treatment of LY294002 or control. Bars, 20 µm.

Tables S1–S5 are available as Excel files. Table S1 lists differential gene expression between Pten"w/w and Pten"fl/fl synovial sarcomas. Table S2 lists ingenuity pathway analysis of potential upstream regulators between Pten"w/w and Pten"fl/fl. Table S3 lists differential gene expression between primary and lung metastases Pten"fl/fl synovial sarcomas. Table S4 lists Ingenuity pathway analysis for potential upstream regulators between primary and lung metastases Pten"fl/fl synovial sarcomas. Table S5 Nanostring gene expression on sorted cell populations with normalized values based on prevalence in flow cytometry.
Table S6. Antibody list

<table>
<thead>
<tr>
<th>Protein</th>
<th>Company (cat. no.)</th>
<th>Application and dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>phopho-Akt</td>
<td>Cell Signaling Technology (4060)</td>
<td>WB [1:1,000]</td>
</tr>
<tr>
<td>pan-Akt</td>
<td>Cell Signaling Technology (4391)</td>
<td>WB [1:1,000]</td>
</tr>
<tr>
<td>phospho-PTEN</td>
<td>Cell Signaling Technology (9551)</td>
<td>WB [1:1,000]</td>
</tr>
<tr>
<td>phospho-CSF1R</td>
<td>Thermo Fisher Scientific [MAS-15151]</td>
<td>WB [1:1,000] and IHC [1:50]</td>
</tr>
<tr>
<td>phospho-Akt</td>
<td>Santa Cruz Biotechnology, Inc. (sc-135650)</td>
<td>WB [1:200] and IHC [1:50]</td>
</tr>
<tr>
<td>GAPDH</td>
<td>EMD Millipore (MAB374)</td>
<td>WB [1:500]</td>
</tr>
<tr>
<td>Ly-6C</td>
<td>BD (560596)</td>
<td>Flow cytometry [1:1,000]</td>
</tr>
<tr>
<td>CD11b</td>
<td>BD (552850)</td>
<td>Flow cytometry [1:1,000]</td>
</tr>
<tr>
<td>MHC II (I-A/I-E)</td>
<td>BD (562367)</td>
<td>Flow cytometry [1:1,000]</td>
</tr>
<tr>
<td>F4/80</td>
<td>BD (565410)</td>
<td>Flow cytometry [1:1,000]</td>
</tr>
<tr>
<td>Ly-6G</td>
<td>BD (580602)</td>
<td>Flow cytometry [1:1,000]</td>
</tr>
<tr>
<td>E-cadherin</td>
<td>RtpD Systems (FAB7481A)</td>
<td>Flow cytometry [1:100]</td>
</tr>
<tr>
<td>CD68</td>
<td>Abcam (ab125212)</td>
<td>IHC [1:500]</td>
</tr>
<tr>
<td>CD3</td>
<td>Abcam (ab16660)</td>
<td>IHC [1:200]</td>
</tr>
<tr>
<td>CD31</td>
<td>Abcam (ab26364)</td>
<td>IHC [1:1,000]</td>
</tr>
<tr>
<td>Ki67</td>
<td>Abcam (ab15580)</td>
<td>IHC [1:1,000]</td>
</tr>
<tr>
<td>GFP</td>
<td>Santa Cruz Biotechnology, Inc. (sc-8334)</td>
<td>IHC [1:100]</td>
</tr>
<tr>
<td>BCL-2</td>
<td>Dako (M0887)</td>
<td>IHC [1:100]</td>
</tr>
<tr>
<td>Pan-CK</td>
<td>EMD Millipore (MAB3412)</td>
<td>IHC [1:1,000]</td>
</tr>
<tr>
<td>TLE1</td>
<td>Santa Cruz Biotechnology, Inc. (sc-9121)</td>
<td>IHC [1:100]</td>
</tr>
<tr>
<td>EMA</td>
<td>Dako (M0613)</td>
<td>IHC [1:100]</td>
</tr>
</tbody>
</table>

Table S7. Primer list

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward sequence (5’-3’)</th>
<th>Reverse sequence (5’-3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rosa26-LSL</td>
<td>GGATCGACGGATCTCTAGAG</td>
<td>CGCGAACGCCACAGACATTT</td>
</tr>
<tr>
<td>CSF1 (mouse)</td>
<td>ACAACACCCCAATCTCTAC</td>
<td>GCTGTTTGTGCAGTCTCTTG</td>
</tr>
<tr>
<td>CSF1 (human)</td>
<td>GAGTCTGTCTTCACAATCTTC</td>
<td>GAATCGCTCTCAGTCTCTC</td>
</tr>
<tr>
<td>GAPDH (mouse)</td>
<td>TGTACGAATGCATCTCAG</td>
<td>CGGTTGCTCTGGAGTGAC</td>
</tr>
<tr>
<td>GAPDH (human)</td>
<td>GTCAAGGCTGAGAAGAGGGAA</td>
<td>GCCCTTCTGAGTCTGAGA</td>
</tr>
<tr>
<td>Rosa wt (genotyping)</td>
<td>GTTATCGTAAAGGCGACGCTAGG</td>
<td>GCGCGATCAACAAGAATATAC</td>
</tr>
<tr>
<td>Rosa lox (genotyping)</td>
<td>AAGACCACGAAAGATTCTTGTCT</td>
<td>GCGCGATCAACAAGAATATAC</td>
</tr>
<tr>
<td>Pten (genotyping)</td>
<td>CAAGCATTCTGGACACTGAG</td>
<td>AAGTTTTTGAAGCCAAATGAC</td>
</tr>
</tbody>
</table>